Viewing nowCombinationRobelito Tablet 300/10 mg (Irbesartan, Atorvastatin)
Atorvastatin Calcium Trihydrate 10.85mg · Irbesartan 300mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 201401984 · Approved 2014.04.24 · Insurance code 643506880
Treatment of hypertension and concomitant diabetic nephropathy, improvement of dyslipidemia, and prevention of cardiovascular disease
This medication contains two ingredients, Irbesartan and Atorvastatin, for use when combination therapy is needed in specific patients. First, Irbesartan is effective for the treatment of essential hypertension and helps prevent nephropathy in patients with Type 2 diabetes who have hypertension. Atorvastatin is used to reduce the risk of cardiovascular disease by lowering the risk of myocardial infarction and stroke in adults with multiple risk factors for coronary artery disease and in patients with Type 2 diabetes. Additionally, it helps reduce various risks related to myocardial infarction, stroke, vascular interventions, and congestive heart failure in patients who already have coronary artery disease. It is also effective in treating hyperlipidemia and is used to reduce total cholesterol and LDL cholesterol levels and increase HDL cholesterol levels in patients with various types of dyslipidemia that are difficult to control with diet. Thus, this medication helps improve heart and vascular health by controlling blood pressure and blood lipid levels.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, irbesartan/atorvastatin. ○ Irbesartan 1. Essential hypertension Adults: Administer irbesartan 150 mg orally once daily; if the effect is insufficient, the dose may be increased to 300 mg. In general, blood pressure control over 24 hours is better with 150 mg once daily than with 75 mg once daily, but 75 mg may be considered in special cases (e.g., at the start of treatment, in patients on hemodialysis, or in elderly patients aged 75 years or older). 2. Nephropathy in patients with type 2 diabetes and hypertension Adults: It is recommended to start oral treatment with 150 mg of this medicine once daily and increase the dose to 300 mg for maintenance. - Elderly patients Dose adjustment is generally not necessary, but an initial dose of 75 mg should be considered in patients aged 75 years or older. - Patients with renal impairment Dose adjustment is generally not necessary, but an initial dose of 75 mg should be considered in patients on hemodialysis. - Patients with hepatic impairment Dose adjustment is generally not specifically required in patients with mild to moderate hepatic impairment, but it is recommended not to exceed 150 mg per day. There is no clinical experience in patients with severe hepatic impairment. ○ Atorvastatin calcium 1. Hyperlipidemia The recommended initial dose is atorvastatin 10 mg once daily, but treatment may be started at 20 mg or 40 mg once daily in patients who require a greater reduction in LDL cholesterol (40 mg only when a reduction in LDL cholesterol of 45 % or more is required). This medicine is administered at a dose of 10 ~ 80 mg once daily. The initial and maintenance doses of this medicine should be individualized according to the patient's characteristics, taking into account treatment goals and response. Lipid levels should be analyzed within 2 ~ 4 weeks after starting treatment and/or dose titration, and the dose adjusted accordingly. Patients with homozygous familial hypercholesterolemia This medicine is administered at a dose of 10 ~ 80 mg once daily, in combination with other lipid-lowering treatments (e.g., LDL apheresis) or when such lipid-lowering treatments are not available. - Patients with renal impairment: Renal disease does not affect plasma concentrations of atorvastatin or its LDL-cholesterol-lowering effect; therefore, dose adjustment is not necessary. - Elderly patients: Efficacy and safety in patients aged 70 years or older are similar to those in the general adult patient population.
This medication should not be used during pregnancy. If pregnancy is confirmed, use should be immediately discontinued as it can cause severe harm to the fetus and newborn. If severe muscle pain or weakness occurs, or if there is a significant increase in creatine kinase levels, use should be immediately discontinued and consulted with a physician. Patients with poor liver function or a history of liver disease should use this medication with caution and undergo regular liver function tests. Patients undergoing treatment for hypertension should closely monitor for changes in symptoms, as hypotension or symptoms such as dizziness or fainting may occur. The risk of side effects can increase when used with specific medications, so inform your physician or pharmacist if you are taking other medications. Since there is a risk of elevated potassium levels, patients with hyperkalemia or those taking potassium supplements should regularly check their serum potassium levels. This medication is not recommended for children, especially those under 18 years of age, as the safety and efficacy have not been established. For elderly patients, there is a risk of excessively low blood pressure, so treatment should start at a low dose, and patients should be carefully monitored. Overdosage can cause hypotension, tachycardia, and other symptoms, so strict adherence to the dosage is necessary, and immediate medical consultation is needed if abnormal symptoms occur. Store in a place out of reach of children and keep in the original container to avoid degradation of quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air or moisture. The storage temperature should be between 1 to 30 degrees Celsius, and it is advisable to avoid excessively hot or cold places.
Pale pink oval film-coated tablet
30 tablets/ bottle, 30 tablets/ box [10 tablets/PTPX3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAtorvastatin Calcium Trihydrate 10.85mg · Irbesartan 300mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationAtorvastatin Calcium Trihydrate 21.7mg · Irbesartan 150mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationAtorvastatin Calcium Trihydrate 10.85mg · Irbesartan 150mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationAtorvastatin Calcium Trihydrate 21.7mg · Irbesartan 300mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.